Aclarion, Inc., a healthcare technology company, develops software application for magnetic resonance spectroscopy (MRS) in the United States. It offers NOCISCAN-LS Post-Processor suite comprising NOCICALC-LS that receives and processes the acquired disc MRS data to calculate levels of degenerative pain biomarkers; and NOCIGRAM-LS, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was founded in 2008 and is based in San Mateo, California.

Aclarion, Inc.

The first, evidence-supported, SaaS platform to leverage MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine.

Tech Coast Angels

Aclarion

Chronic low back pain is a life-changing condition that prevents many individuals from living full and healthy lives. And finding the right treatment option for each patient’s unique situation can take months, if not years, to find. 
 
With Nociscan, patient-specific biomarker data helps physicians quickly assess which discs are potentially the source of a patient’s pain so physicians can optimize treatment strategies and help patients get back to an active, pain-free life.
 
Patients around the world are already experiencing the benefits of Nociscan. To learn more about how Nociscan can help you or a loved one, visit www.aclarion.com.
 
#ACON #ACONW #spine #nasdaq #lowbackpain

Last weekend at ISASS 2023, Leslie Wilson presented a cost-effectiveness abstract overviewing the initial findings of the EVAL study (Economic Value Analysis of Low back pain). The study found that Nociscan demonstrated statistical dominance over provocative discography with the potential to save the US healthcare system $283M to $441M annually. Read the full release here. https://lnkd.in/gMNt2uMw

#ACON #ACONW #nasdaq #lowbackpain #nociscan #spinesurgery #ISASS

New and compelling healthcare economics data from the EVAL Study (Economic Value Analysis of Low back pain Study) will be presented this week at ISASS 2023 in San Francisco! 

Join Aclarion on Saturday, June 3 in Salon 13-15 at 10:34 am to learn about the initial findings of this pivotal economic analysis of the Nociscan solution for the treatment of low back pain. 

Presentation title: Cost-effectiveness of novel, non-invasive diagnostic test for chronic low back pain. 
Presenter: Leslie Wilson, Professor at UCSF. 

#ACON #ACONW #ISASS23 #lowbackpain #spinesurgery #nasdaq

Aclarion announced today their commercial agreement with the prestigious London Clinic and London Spine Clinic. The London Clinic is one of the UK’s largest and most renowned independent hospitals. Based in the heart of London’s medical district, the Clinic has a heritage of investing in the latest technologies and providing exceptional medical care through state-of-the-art facilities.

“The engagement with Aclarion will allow London Spine Clinic to continue offering the high-quality care our patients have come to expect. Patients need a careful assessment, diagnosis, and understanding of the different treatment options available to them.  Aclarion’s innovative Nociscan solution will enable us to objectively assess biomarkers associated with low back pain and enhance the precision of each diagnosis,” said John Sutcliffe MD, Neurosurgeon, and Founder of London Spine Clinic.

Read the full announcement here. https://lnkd.in/gAmfkDQT

#ACON #ACONW #nasdaq #londonspineclinic #londonclinic #nociscan #spinesurgery

Aclarion’s CEO Brent Ness was recently interviewed by Proactive about the value of the Nociscan solution when treating patients with chronic low back pain and the corporate milestones that the company has recently achieved. Watch the full interview here. https://lnkd.in/gzEPAhkm

#ACON #ACONW #nasdaq #nociscan #lowbackpain #spine #spinesurgery

Wonderful Aclarion symposium today at SpineWeek in Melbourne. Standing room only to hear spine experts Sigurd Berven MD and Jeff Lotz PhD discuss the value of the Nociscan solution in addressing the question of Where’s the Pain? The clinical and economic data are clear: Nociscan improves clinical outcomes and has the potential to significantly reduce the cost of care. Visit www.aclarion.com to learn how you can bring Nociscan to your spine center. 

#ACON #ACONW #nasdaq #spineweek #painmanagement #pain #nociscan #spinesurgery

Attending SpineWeek in Melbourne next week? If so, join us Tuesday, May 2 for a sponsored symposium, Where’s The Pain?, led by renowned spine experts Sigurd Berven, MD and Jeff Lotz, PhD. New clinical and economic data will be presented demonstrating the value of the Nociscan solution to aid in the treatment of chronic low back pain. Hope to see you there.

#ACON #ACONW #nociscan #spineweek #spine #nasdaq #pain #painmanagement

We’re excited to announce the publication of two-year durability data which demonstrates improved surgical outcomes for discogenic low back pain (DLBP) surgeries at chemically painful lumbar discs identified by Nociscan. Success rates at 2 years for DLBP low back pain surgeries was 85% for patients whose treatment strategy was consistent with Nociscan-identified discs, a 22 percentage point improvement over patients whose treatment strategy was inconsistent with Nociscan-identified discs. (85% vs. 63%; p=0.07). Access the full article at https://lnkd.in/dCREgnkE

#ACON #ACONW #spinesurgery #nociscan #lowbackpain

Great debate last Friday at the 2023 Annual AANS/CNS Spine Summit between Juan Uribe, MD and Christopher Ames, MD on the role of AI and ML in spine surgery. Important topics raised by both sides and clearly, the future of spine care will be influenced by this growing field. 

Thank you, Dr. Uribe and Dr. Ames, for your continued commitment to advancing care for patients suffering from chronic low back pain.

#ACON #ACONW #spine #AI #machinelearning

Great topic for a debate! Looking forward to tomorrow's discussion.

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
asset turnover	0.02 -	0.04 100.30%	0.03 15.28%	0.02 40.92%
cash conversion cycle	-2.70K -	-4.57K 69.46%	-5.55K 21.58%	-761.14 86.29%
cash per share	0.02 -	0.00 88.31%	0.06 3,189.87%	0.24 282.77%
company equity multiplier	-0.84 -	-0.18 78.30%	-0.33 80.85%	1.79 643.77%
days of inventory outstanding				1.68K -
days of payables outstanding	2.89K -	4.74K 63.61%	5.59K 18.05%	2.56K 54.25%
days of sales outstanding	199.42 -	168.82 15.34%	38.02 77.48%	112.13 194.94%
dividend yield				0.12 -
ebit per revenue	-149.21 -	-92.03 38.32%	-48.98 46.78%	-100.90 106.00%	-64.66 35.91%
ebt per ebit	1.00 -	1.04 3.37%	1.68 61.93%	1.25 25.60%	1.01 19.23%
effective tax rate	-0.00 -	-0.03 2,682.12%	0.29 954.50%	-0.20 169.25%
enterprise value multiple	-5.65 -	-5.52 2.27%	-4.53 17.98%	-0.35 92.26%
fixed asset turnover	0.55 -	1.90 242.52%	4.77 151.23%	18.06 278.60%
free cash flow per share	-0.57 -	-0.51 10.45%	-0.35 31.43%	-0.90 159.62%	-6.55 624.06%
gross profit margin	-1.35 -	-0.36 73.19%	-0.15 59.26%	-0.08 45.49%	-0.00 94.65%
interest coverage	-803.46 -	-28.69 96.43%	-6.20 78.40%	-4.05 34.73%	8.02 298.15%
inventory turnover				0.22 -
long term debt to capitalization
net income per ebt	1.00 -	1.03 3.22%	0.71 30.91%	1.20 67.79%	1 16.53%
net profit margin	-149.61 -	-98.46 34.19%	-58.62 40.46%	-150.75 157.14%	-65.13 56.79%
operating cash flow per share	-0.53 -	-0.49 9.01%	-0.33 32.55%	-0.87 165.96%	-6.55 652.51%
operating cycle	199.42 -	168.82 15.34%	38.02 77.48%	1.80K 4,625.35%
operating profit margin	-149.21 -	-92.03 38.32%	-48.98 46.78%	-100.90 106.00%	-64.66 35.91%
payables turnover	0.13 -	0.08 38.88%	0.07 15.29%	0.14 118.59%
pretax profit margin	-149.43 -	-95.27 36.24%	-82.11 13.82%	-125.83 53.25%	-65.13 48.24%
price fair value	-12.50 -	-3.00 75.97%	-3.41 13.50%	1.98 158.11%
receivables turnover	1.83 -	2.16 18.13%	9.60 344.04%	3.26 66.09%
return on assets	-2.81 -	-3.71 31.82%	-1.87 49.56%	-2.84 51.93%
return on capital employed	2.36 -	0.63 73.19%	0.52 18.46%	-3.41 761.84%
return on equity	2.36 -	0.68 71.40%	0.62 8.77%	-5.10 926.15%
total debt to capitalization	-0.43 -	-0.50 16.21%	-0.54 6.20%

COM:ACLARION

Aclarion, Inc.

Last Close

0.18

22/11 21:00

Market Cap

2.49M

Beta: -

Volume Today

124.21K

Avg: -

Preview